CONCORDBIO - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 4.1
| Stock Code | CONCORDBIO | Market Cap | 11,500 Cr. | Current Price | 1,099 ₹ | High / Low | 2,150 ₹ |
| Stock P/E | 36.2 | Book Value | 174 ₹ | Dividend Yield | 0.97 % | ROCE | 28.4 % |
| ROE | 21.4 % | Face Value | 1.00 ₹ | DMA 50 | 1,131 ₹ | DMA 200 | 1,318 ₹ |
| Chg in FII Hold | 0.21 % | Chg in DII Hold | -0.36 % | PAT Qtr | 70.2 Cr. | PAT Prev Qtr | 62.9 Cr. |
| RSI | 45.3 | MACD | 4.98 | Volume | 1,46,585 | Avg Vol 1Wk | 1,17,220 |
| Low price | 987 ₹ | High price | 2,150 ₹ | PEG Ratio | 1.35 | Debt to equity | 0.00 |
| 52w Index | 9.66 % | Qtr Profit Var | -5.20 % | EPS | 30.1 ₹ | Industry PE | 31.6 |
📈 Chart & Trend Analysis: CONCORDBIO is trading at ₹1,099, below its 50 DMA (₹1,131) and 200 DMA (₹1,318), indicating short-term weakness. RSI at 45.3 suggests mild bearish momentum but not oversold. MACD at 4.98 is positive, hinting at potential recovery. Bollinger Bands show price near the lower band, suggesting possible support around ₹1,080–₹1,090.
🔎 Momentum Signals: Current volume (1.46L) is higher than the 1-week average (1.17L), showing active participation. Short-term momentum is mixed, with downside pressure but potential for rebound if support holds.
🎯 Entry Zone: ₹1,080–₹1,090 (support cluster)
🚪 Exit Zone: ₹1,145–₹1,160 (resistance zone)
🛑 Stop-Loss: ₹1,060 (below recent support)
📊 Trend Status: Consolidating with a slight bearish bias; potential reversal if price sustains above ₹1,100 and breaks ₹1,145 resistance.
Positive
- Strong ROE (21.4%) and ROCE (28.4%) indicate efficient capital use.
- Debt-free balance sheet (0.00 debt-to-equity) adds financial strength.
- PEG ratio at 1.35 suggests reasonable valuation relative to growth.
- EPS at ₹30.1 supports long-term earnings visibility.
Limitation
- Stock trading below both 50 DMA and 200 DMA signals weakness.
- High P/E (36.2) compared to industry PE (31.6) limits valuation comfort.
- Quarterly profit decline (-5.20%) raises near-term concerns.
Company Negative News
- DII holdings decreased (-0.36%), showing reduced domestic institutional confidence.
- Quarterly PAT fell from ₹62.9 Cr. to ₹70.2 Cr. with negative variation.
Company Positive News
- FII holdings increased (+0.21%), reflecting foreign investor interest.
- Stable EPS and consistent profitability despite recent volatility.
Industry
- Industry PE at 31.6 shows sector remains moderately valued.
- Biopharma sector continues to benefit from innovation and demand growth.
Conclusion
✅ CONCORDBIO is consolidating with mild bearish undertones but retains strong fundamentals. Traders can consider entry near ₹1,080–₹1,090 with exit around ₹1,145–₹1,160. Long-term investors may hold given debt-free status and strong ROE/ROCE, though short-term caution is warranted due to weak technicals and profit decline.
Would you like me to adapt this into a reusable biopharma trade template for sector-wide benchmarking, or keep it focused as a single CONCORDBIO analysis?